Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)

Phase I Pharmacokinetics Study of Oral Administration of Esperavir® (INN: Molnupiravir) (LLC "PROMOMED RUS", Russia)

Introduction. The pandemic of the new coronavirus infection COVID-19 (Coronavirus Disease 2019) was caused by a single-stranded RNA virus SARS-CoV-2 (Severe acute respiratory syndrome-related coronavirus 2). Molnupiravir is an antiviral drug with activity against RNA viruses including SARS-CoV-2. Mo...

Full description

Saved in:
Bibliographic Details
Main Authors: T. N. Komarov, N. S. Bagaeva, K. K. Karnakova, K. Ya. Zaslavskaya, P. A. Bely, I. E. Shohin
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2024-03-01
Series:Разработка и регистрация лекарственных средств
Subjects:
molnupiravir
covid-19
pharmacokinetics
Online Access:https://www.pharmjournal.ru/jour/article/view/1754
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.pharmjournal.ru/jour/article/view/1754

Similar Items